RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050

RealRate

July 10, 2026

To the CEO
Agios Pharmaceuticals INC
88 SIDNEY STREET
CAMBRIDGE, MA 02139
USA

Agios Pharmaceuticals INC TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Agios Pharmaceuticals INC has been TOP Rated at rank 12 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at https://www.realrate.ai/rankings. Your individual rating report, showing your strengths compared to your competitors is attached.

TOP RATED 2026 RealRate

agios

RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just $9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: https://calendly.com/holger-bartel

Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Agios Pharmaceuticals INC. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.

RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Agios Pharmaceuticals INC (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	**2026 US Pharmaceutical RealRate rating seal for Agios Pharmaceuticals INC**
Amount	**USD 9,900**
Order no.	2026-0001439222

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address

Company name		Full name	
Street address		Department	
City		Phone number	
State / provice		Email address	
ZIP code			
Country			

Shipping address
The electronic RealRate rating seal and the invoice will be sent to

Delivery email

Agios Pharmaceuticals INC

Date, location, name

Agios Pharmaceuticals INC

Rank 12 of 178



PHARMACEUTICAL 2026

Agios Pharmaceuticals INC
Rank 12 of 178

The relative strengths and weaknesses of Agios Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Agios Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 171% points.The greatest weakness of Agios Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 377%, being 148% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	942,052
Cost of Goods Sold	6,345
Intangible Assets	0
Liabilities, Current	82,206
Liabilities, Non-Current	21,905
Other Assets	344,398
Other Compr. Net Income	3,711
Other Expenses	-1,016
Other Liabilities	0
Other Net Income	58,335
Other Revenues	54,028
Property and Equipment	10,775
Research and Development	339,535
Selling, General and Administrative Expense	180,280

Output Variable	Value in 1000 USD
Assets	1,297,225
Liabilities	104,111
Expenses	525,144
Revenues	54,028
Stockholders Equity	1,193,114
Net Income	-412,781
Comprehensive Net Income	-410,926
BaseVar	1,021,277
ECR before LimitedLiability	313%
Economic Capital Ratio	377%